Evidence map›Paper›PMID 24518000›Full record

ReviewQJM : monthly journal of the Association of Physicians2014

Mesenchymal stem cells, autoimmunity and rheumatoid arthritis.

J J El-Jawhari, Y M El-Sherbiny, E A Jones, D McGonagle

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in QJM : monthly journal of the Association of Physicians, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  10. Scaffolded Chondrogenic Spheroid-Engrafted Model.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Mesenchymal stem cells and their microenvironment.Stem cell research & therapy · 2022
    Review
  16. Article
  17. Review
  18. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J J El-JawhariFrom the Leeds Institute of Rheumatic and Musculoskeletal Medicine, St. James University Hospital , WTBB, LS9 7TF University of Leeds, UK and Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, EgyptFrom the Leeds Institute of Rheumatic and Musculoskeletal Medicine, St. James University Hospital , WTBB, LS9 7TF University of Leeds, UK and Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Y M El-SherbinyFrom the Leeds Institute of Rheumatic and Musculoskeletal Medicine, St. James University Hospital , WTBB, LS9 7TF University of Leeds, UK and Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, EgyptFrom the Leeds Institute of Rheumatic and Musculoskeletal Medicine, St. James University Hospital , WTBB, LS9 7TF University of Leeds, UK and Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
E A JonesFrom the Leeds Institute of Rheumatic and Musculoskeletal Medicine, St. James University Hospital , WTBB, LS9 7TF University of Leeds, UK and Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
D McGonagleFrom the Leeds Institute of Rheumatic and Musculoskeletal Medicine, St. James University Hospital , WTBB, LS9 7TF University of Leeds, UK and Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt D.G.McGonagle@leeds.ac.uk.

Funding

Wellcome Trust WT088908/Z/09/Z
6 · The paper itself

Abstract

The vast majority of literature pertaining to mesenchymal stem cells (MSC) immunomodulation has focussed on bone marrow-derived MSC that are systemically infused to alleviate inflammatory conditions. Rheumatoid arthritis (RA) is the commonest autoimmune joint disease that has witnessed significant therapeutic advances in the past decade, but remains stubbornly difficult to treat in a subset of cases. Pre-clinical research has demonstrated that bone marrow, adipose, synovial and umbilical cord-derived MSC all suppress the functions of different immune cells thus raising the possibility of new therapies for autoimmune diseases including RA. Indeed, preliminary evidence for MSC efficacy has been reported in some cases of RA and systemic lupus erythromatosis. The potential use of bone marrow-MSC (BM-MSC) for RA therapy is emerging but the use of synovial MSC (S-MSC) to suppress the exaggerated immune response within the inflamed joints remains rudimentary. Synovial fibroblasts that are likely derived from S-MSCs, also give rise to a cell-cultured progeny termed fibroblast-like synoviocytes (FLS), which are key players in the perpetuation of joint inflammation and destruction. A better understanding of the link between these cells and their biology could be a key to developing novel MSC-based strategies for therapy. The review briefly focuses on BM-MSC and gives particular attention to joint niche synovial MSC and FLS with respect to immunoregulatory potential therapy roles.

Indexed as

AutoimmunityArthritis, RheumatoidFibroblastsHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationSynovial Membrane

Identifiers

PMID24518000
PMCPMC4071294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.